Predictive Value of Midregional Pro–Atrial Natriuretic Peptide for Cardioembolic Stroke in Hyperacute Ischemic Stroke-Reference-Cited by-同舟云学术

Predictive Value of Midregional Pro–Atrial Natriuretic Peptide for Cardioembolic Stroke in Hyperacute Ischemic Stroke

Published:2024-06-04 Issue:11 Volume:13 Page:
ISSN:2047-9980
Container-title:Journal of the American Heart Association
language:en
Short-container-title:JAHA

Author:

Ikenouchi Hajime¹^ORCID,Saito Satoshi¹^ORCID,Ishiyama Hiroyuki¹,Kitamura Akihiro²^ORCID,Tanaka Tomotaka¹^ORCID,Inoue Manabu³^ORCID,Takahashi Yukako¹^ORCID,Koyama Teruhide⁴^ORCID,Kuriyama Nagato⁴⁵^ORCID,Koga Masatoshi³^ORCID,Toyoda Kazunori³^ORCID,Urushitani Makoto²^ORCID,Ihara Masafumi¹^ORCID

Affiliation:

1. Department of Neurology, National Cerebral and Cardiovascular Center Suita Japan

2. Department of Neurology Shiga University of Medical Science Otsu Japan

3. Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center Suita Japan

4. Department of Epidemiology for Community Health and Medicine Kyoto Prefectural University of Medicine Kyoto Japan

5. Shizuoka Graduate University of Public Health Shizuoka Japan

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference5 articles.

1. Measurement of Midregional Pro-Atrial Natriuretic Peptide to Discover Atrial Fibrillation in Patients With Ischemic Stroke

2. Midregional proatrial natriuretic peptide improves risk stratification after ischemic stroke

3. Independent Prognostic Value of MRproANP (Midregional Proatrial Natriuretic Peptide) Levels in Patients With Stroke Is Unaltered Over Time

4. Immunoluminometric Assay for the Midregion of Pro-Atrial Natriuretic Peptide in Human Plasma

5. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.